Integration of 24-h Urine Aldosterone & Tetrahydroaldosterone With Plasma Screening for Primary Aldosteronism: A 7-Year Study
In brief
Adding urine markers raises primary aldosteronism screening sensitivity to 89%
In a 1,076-patient retrospective study, combining 24-hour urine aldosterone markers with plasma tests detected 89% of primary aldosteronism cases, compared with 66% using guideline-based screening, with similar specificity. The combined approach had a 97% negative predictive value, but its 59% positive predictive value means positive screens still need confirmation; prospective testing will show how well it performs in routine care.
- Journal
- Journal of clinical hypertension (Greenwich, Conn.) (Q2)
- Published
- 1 November 2026
- Study design
- Cohort / observational study
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Jenny Yeuk Ki Cheng, Timothy Hua-Tse Cheng, Edith Wing Kar Chow, Wendy Wan Hang Lau, Kitty Kit Ting Cheung, Clara Wai Shan Lo, et al.
- PMID
- 43061815
- DOI
- 10.1111/jch.70390
Why clinicians should know about it
- Picked for Biochemistry (medical) (top studies of the week, 22 November 2026): LC-MS/MS urinary steroid assay integrated with plasma aldosterone screening
Abstract
Plasma-based screening for primary aldosteronism (PA), namely aldosterone-to-renin ratio, plasma aldosterone concentration (PAC), and plasma renin activity (PRA), is influenced by short-term physiologic variation and medications. Non-salt-loaded 24-h urine collection may complement plasma screening. In this multicenter retrospective observational study (October 2013-September 2020), non-salt-loaded 24-h urinary aldosterone (UALD) and tetrahydroaldosterone (UTHA) were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in patients evaluated for PA. A chronological derivation (2013-2015) and validation (2015-2020) design was used. Optimal cutoffs for UALD, UTHA, and their sum (SUM) were derived using ROC analysis with bootstrapping. In patients with paired urine and plasma measurements, logistic models were developed for a urine panel (UALD, UTHA), a plasma panel (PAC, PRA), and a combined panel. A points-based Combined Urine-Plasma Score (CUPS) was constructed for clinical implementation. Among 1316 eligible cases, derived cutoffs were UALD >39 nmol/day, UTHA >179 nmol/day, and SUM >190 nmol/day, all with AUCs of 0.84-0.85. In 1076 cases, AUCs were 0.85 for the urine panel, 0.89 for the plasma panel, and 0.93 for the combined panel. The combined panel achieved 89% sensitivity and 84% specificity (positive predictive value 59%, negative predictive value (NPV) 97%), improving sensitivity compared with Endocrine Society rule-based screening (66%) but with similar specificity (89%). CUPS showed comparable performance (sensitivity 85%, specificity 86%, NPV 96%). Non-salt-loaded 24-h urinary aldosterone biomarkers measured by LC-MS/MS provide robust screening performance and add incremental value to plasma-based screening. Integrating urine and plasma markers (including CUPS) may improve PA detection in routine practice.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.